David Schaaf
Chief Tech/Sci/R&D Officer chez PDS BIOTECHNOLOGY CORPORATION
Profil
David Schaaf is currently the Vice President-Medical Affairs at PDS Biotechnology Corp.
He previously worked as the Vice President-Medical Affairs at Zogenix, Inc. Schaaf has a graduate degree from The Trustees of Columbia University in The City of New York and an undergraduate degree from Stanford University.
Postes actifs de David Schaaf
| Sociétés | Poste | Début |
|---|---|---|
| PDS BIOTECHNOLOGY CORPORATION | Chief Tech/Sci/R&D Officer | 01/09/2022 |
Anciens postes connus de David Schaaf
| Sociétés | Poste | Fin |
|---|---|---|
| ZOGENIX, INC. | Chief Tech/Sci/R&D Officer | - |
Formation de David Schaaf
| The Trustees of Columbia University in The City of New York | Graduate Degree |
| Stanford University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PDS BIOTECHNOLOGY CORPORATION | Health Technology |
| Entreprise privées | 1 |
|---|---|
Zogenix, Inc.
 Zogenix, Inc. Pharmaceuticals: MajorHealth Technology Zogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA. | Health Technology |
